Related Experiment Video
Updated: May 14, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Progress in the Research and Development of Biphenyl Small Molecules Targeting PD-1/PD-L1 as Potential Antitumor Drug
Wei He1,2, Haoran Xu1,2, Annoor Awadasseid1,2,3
1Lab of Chemical Biology and Molecular Drug DesignCollege of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China.
Abstract:
Cancer remains a major global health challenge, and cancer immunotherapy has emerged as a promising treatment strategy. A key immune checkpoint in this approach is the interaction between PD-1 and PD-L1, which suppresses immune responses against tumor cells. Although monoclonal antibodies targeting PD-1/PD-L1 have shown significant therapeutic potential, their use is hampered by limitations such as high costs, extended half-lives, and the potential for immune-related side effects. In response to these challenges, there is growing interest in the development of small-molecule inhibitors that can disrupt the PD-1/PD-L1 interaction more efficiently and cost-effectively. This review focuses on the design of biphenyl-based small molecules as inhibitors of the PD-1/PD-L1 pathway. We explore various design strategies, key structural features, and recent advancements in biphenyl-derived compounds. These insights contribute to the ongoing effort to develop alternative antitumor therapies with improved pharmacological profiles and therapeutic efficacy.
Insights
Small molecules targeting the PD-1/PD-L1 pathway offer a promising alternative to antibodies for cancer immunotherapy. Biphenyl-based inhibitors are being developed for more efficient and cost-effective antitumor therapies.
Area of Science:
- Oncology
- Immunology
- Medicinal Chemistry
Background:
- Cancer immunotherapy utilizes immune checkpoints like PD-1/PD-L1 to enhance anti-tumor responses.
- Monoclonal antibodies targeting PD-1/PD-L1 are effective but face challenges including high cost and side effects.
Purpose of the Study:
- To review the design strategies for biphenyl-based small molecules as inhibitors of the PD-1/PD-L1 pathway.
- To explore advancements in biphenyl-derived compounds for cancer treatment.
Main Methods:
- Literature review of biphenyl-based small molecule inhibitors.
- Analysis of design strategies and key structural features.
- Examination of recent advancements in the field.
Main Results:
- Biphenyl scaffolds offer a viable structural basis for developing small-molecule PD-1/PD-L1 inhibitors.
- Various design approaches have yielded promising compounds with potential therapeutic efficacy.
- These small molecules aim to overcome limitations associated with antibody therapies.
Conclusions:
- Biphenyl-based small molecules represent a promising avenue for developing novel cancer immunotherapies.
- These inhibitors offer potential advantages in terms of cost-effectiveness and pharmacological profiles.
- Further research into biphenyl derivatives could lead to improved antitumor therapies.
